Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Infect Dis (Lond) ; 50(10): 743-748, 2018 Oct.
Article in English | MEDLINE | ID: mdl-29745277

ABSTRACT

OBJECTIVES: Staphylococcus aureus bacteraemia (SAB) is a common infection associated with significant short-term mortality. Little is known about long-term prognosis. The aim of this study was to determine one-year all-cause mortality and infection-related mortality and associated predictors. METHODS: Data from 303 consecutive patients with SAB were prospectively collected from March 2011 to February 2014. All patients were followed one year or until death. RESULTS: One-year all-cause- and infection-related mortality were 36.7% and 20.8%, respectively. For all-cause mortality, in multivariable logistic regression analysis, age 70-79 years (OR 3.9; 95% CI 1.7-9.1; p = .001), Charlson Comorbidity index ≥3 (OR 6.9; 95% CI 2.7-17.3; p < .001), healthcare-associated infection (OR 2.3; 95% CI 1.1-4.9; p = .03) and severe sepsis (OR 3.6; 95% CI 1.8-7.1; p < .001) were independent predictors of outcome. For infection-related mortality, the predictors were similar, except for healthcare-associated infection that lost significance. The vast majority (89%) of infection-related deaths occurred within 30 days. CONCLUSIONS: This study demonstrates additional significant all-cause mortality in patients with SAB beyond 30 days to one year, mainly driven by high age and comorbidity. As a result, SAB can be considered an indirect marker of high risk of death in these patients. Follow-up beyond 30 days does not add significant information with respect to infection-related mortality.


Subject(s)
Bacteremia/mortality , Cross Infection/mortality , Staphylococcal Infections/mortality , Adolescent , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Comorbidity , Cross Infection/microbiology , Female , Humans , Male , Middle Aged , Prognosis , Risk Factors , Staphylococcus aureus/isolation & purification , Young Adult
2.
Cancer Epidemiol ; 38(6): 741-7, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25454262

ABSTRACT

BACKGROUND AND AIMS: Curative treatment of hepatocellular carcinoma (HCC) is dependent on early diagnosis. Surveillance of patients at high risk for HCC is a key determinant to achieve this goal, but may be an underutilized tool. The aim of this study was to determine the rate of pre-diagnosis surveillance in patients with HCC in a large population-based cohort and to assess to what extent cirrhosis was known prior to the diagnosis of HCC. METHODS: All patients diagnosed with HCC during 2000-2009 in The South-Eastern Regional Health Authority, representing 56% of the Norwegian population, were identified from The National Cancer Registry and the medical records were reviewed. RESULTS: Fifteen out of 486 patients (3%) were diagnosed by surveillance. Potential curative treatment was offered to 58% of the patients who underwent surveillance as opposed to 15% in the non-surveillance group. Only age ≤ 65 years was an independent predictor of screening in a multivariate model. Almost two thirds of the patients with cirrhosis were unrecognized prior to the HCC diagnosis. Two hundred and fourteen patients (44%) were non-cirrhotics. CONCLUSION: Regular HCC surveillance in at-risk populations is virtually not applied in Norway and this may contribute to inferior overall survival. Failure to recognize cirrhosis and a high rate of HCC in non-cirrhotic patients will be limiting factors for the overall effectiveness of a potential surveillance program.


Subject(s)
Carcinoma, Hepatocellular/diagnosis , Liver Neoplasms/diagnosis , Carcinoma, Hepatocellular/epidemiology , Carcinoma, Hepatocellular/etiology , Cohort Studies , Early Detection of Cancer , Female , Humans , Liver Neoplasms/epidemiology , Liver Neoplasms/etiology , Male , Norway , Risk Factors
3.
Eur J Gastroenterol Hepatol ; 24(8): 890-6, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22584257

ABSTRACT

OBJECTIVES: Two functional genetic variants in the inosine triphosphatase (ITPA) gene have been shown to be strongly associated with protection from ribavirin (RBV)-induced hemolysis. We aimed at evaluating this finding in a chronic hepatitis C genotype 2/3 cohort with a predominance of genotype 3 patients where available data are scarce. A second objective was to determine whether a protective association translated into the need for RBV reduction and hence a possible impact on treatment response. METHODS: Overall, 457 patients were recruited from two trials of genotype 2/3 patients treated with pegylated interferon α-2b and weight-based RBV. rs1127354 and rs7270101 were genotyped and a composite ITPAase deficiency variable was graded according to the two single nucleotide polymorphisms. The primary endpoints were hemoglobin (Hb) decline from baseline and Hb decline of more than 3 g/dl at week 4. RESULTS: Both single nucleotide polymorphisms and the composite ITPAase deficiency variable were strongly and independently associated with protection from a decline in Hb at week 4 in multivariate linear regression models (Prs1127354=7.0×10, Prs7270101=0.0036, PITPase deficiency variable =6.3×10). Patients with any degree of reduced ITPAase activity were less likely to have their RBV dose reduced (odds ratio 0.39, 95% confidence interval 0.16-0.96, P=0.040), although this did not translate into increased rapid viral response or sustained viral response (Prvr=0.93, Psvr=0.22). CONCLUSION: We have confirmed a strong association between functional ITPA variants and RBV-induced hemolysis and showed protection from RBV dose reduction, although this did not translate into increased rapid viral response or sustained viral response.


Subject(s)
Anemia, Hemolytic/prevention & control , Antiviral Agents/adverse effects , Hepacivirus/genetics , Hepatitis C, Chronic/genetics , Pyrophosphatases/genetics , Ribavirin/adverse effects , Adult , Anemia, Hemolytic/chemically induced , Antiviral Agents/administration & dosage , Clinical Trials as Topic , Cohort Studies , Drug Therapy, Combination , Female , Genetic Variation/genetics , Genotype , Hemoglobins/analysis , Hepatitis C, Chronic/drug therapy , Humans , Interferon alpha-2 , Interferon-alpha/administration & dosage , Male , Polyethylene Glycols/administration & dosage , Polymorphism, Single Nucleotide , Recombinant Proteins/administration & dosage , Ribavirin/administration & dosage , Scandinavian and Nordic Countries , Treatment Outcome
4.
Scand J Infect Dis ; 39(2): 179-80, 2007.
Article in English | MEDLINE | ID: mdl-17366041

ABSTRACT

Infections due to Mycobacterium terrae complex are rare. We report a severe case of chronic tenosynovitis and osteomyelitis of the hand caused by Mycobacterium nonchromogenicum requiring second ray finger amputation.


Subject(s)
Mycobacterium Infections, Nontuberculous/diagnosis , Osteomyelitis/microbiology , Tenosynovitis/microbiology , Aged , Humans , Male , Mycobacterium Infections, Nontuberculous/microbiology , Mycobacterium Infections, Nontuberculous/therapy , Osteomyelitis/therapy , Tenosynovitis/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...